new oral glp 1 agonist Orforglipron, an Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Will New Oral GLP-1 Agonists

Concurrently, Structure Therapeutics is advancing an APJ-targeting molecule into Phase 2 evaluation for obesity, suggesting that the target remains of clinical interest when candidate molecules are appropriately selected

The history of medical therapy in obesity has been frustrating: many treatments were not effective at all

Albanese MJ, Pies R

Overall, its important to review your policy or reach out to the insurance company to understand the specifics of your coverage

While lifestyle modifications such as dietary changes, increased physical activity, and behavioral therapy remain the foundation of treatment, their long-term effectiveness is often limited, especially in cases of severe obesity